Key Takeaways
- Hundreds of FDA probationary employees were dismissed under the Trump Administration’s workforce reductions.
- While the biologics and oncology centers largely were spared, CDER is reported to have lost dozens of people.
- Industry is waiting for the dust to settle before it can fully assess the potential impacts on drug development, which could include delays in inspections and application reviews.
The biopharmaceutical industry likely will feel the impact of the Trump Administration’s weekend purge of hundreds of US Food and Drug Administration probationary employees in many ways over the coming...
For now, stakeholders are waiting for the dust to settle to gain a clearer picture of who has been laid off, as well as how the staff reductions may impact...